PSORS13
MCID: PSR018
MIFTS: 41

Psoriasis 13 (PSORS13)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis 13

MalaCards integrated aliases for Psoriasis 13:

Name: Psoriasis 13 56 12 73 15
Psoriasis Susceptibility 13 56 29 13 6
Psors13 56 12 73
Psoriasis Vulgaris 73 71
Psoriasis 73 71
Psoriasis, Susceptibility to, Type 13 39
Psoriasis 13, Susceptibility to 56
Pv 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0111287
OMIM 56 614070
OMIM Phenotypic Series 56 PS177900
MeSH 43 D011565
MedGen 41 C3279754
UMLS 71 C0033860 C0263361

Summaries for Psoriasis 13

UniProtKB/Swiss-Prot : 73 Psoriasis 13: A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

MalaCards based summary : Psoriasis 13, also known as psoriasis susceptibility 13, is related to guttate psoriasis and pustular psoriasis, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 13 is TRAF3IP2 (TRAF3 Interacting Protein 2). The drugs Esomeprazole and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotype is digestive/alimentary.

Disease Ontology : 12 A psoriasis that has material basis in variation in TRAF3IP2 on chromosome 6q21.

More information from OMIM: 614070 PS177900

Related Diseases for Psoriasis 13

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 13 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1274)
# Related Disease Score Top Affiliating Genes
1 guttate psoriasis 12.7
2 pustular psoriasis 12.7
3 psoriasis 15, pustular 12.6
4 psoriasis 4 12.6
5 psoriasis 3 12.6
6 psoriasis 6 12.6
7 psoriasis 10 12.6
8 psoriasis 5 12.6
9 psoriasis 12 12.6
10 psoriasis 8 12.6
11 psoriasis 9 12.6
12 psoriatic arthritis 12.5
13 psoriasis 15 12.5
14 polycythemia vera 12.5
15 mental retardation and psoriasis 12.3
16 pustulosis palmaris et plantaris 12.3
17 tranebjaerg svejgaard syndrome 12.1
18 psoriatic juvenile idiopathic arthritis 11.9
19 psoriasis 1 11.9
20 impetigo herpetiformis 11.8
21 juvenile rheumatoid arthritis 11.7
22 geographic tongue 11.6
23 pemphigus 11.6
24 parapsoriasis 11.6
25 pemphigus vulgaris, familial 11.6
26 arthritis 11.5
27 persistent vegetative state 11.5
28 pulmonary valve stenosis 11.5
29 spondyloarthropathy 1 11.5
30 vitiligo-associated multiple autoimmune disease susceptibility 1 11.5
31 psoriasis 14, pustular 11.5
32 chronic recurrent multifocal osteomyelitis 11.4
33 temporomandibular ankylosis 11.4
34 singleton-merten syndrome 1 11.2
35 rheumatoid factor-negative juvenile idiopathic arthritis 11.2
36 systemic onset juvenile idiopathic arthritis 11.2
37 variegate porphyria 11.2
38 psoriasis 2 11.2
39 psoriasis 7 11.2
40 psoriasis 11 11.2
41 skin disease 11.2
42 nail disorder, nonsyndromic congenital, 1 11.1
43 combined cellular and humoral immune defects with granulomas 11.1
44 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.1
45 singleton-merten syndrome 2 11.1
46 primary cutaneous amyloidosis 11.1
47 singleton-merten syndrome 11.1
48 dermatitis 11.0
49 dermatitis, atopic 10.9
50 autoimmune disease 10.8

Graphical network of the top 20 diseases related to Psoriasis 13:



Diseases related to Psoriasis 13

Symptoms & Phenotypes for Psoriasis 13

Clinical features from OMIM:

614070

UMLS symptoms related to Psoriasis 13:


pruritus, exanthema, psoriasiform rash

MGI Mouse Phenotypes related to Psoriasis 13:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 8.92 FEN1 FST MCOLN1 TRAF3IP2

Drugs & Therapeutics for Psoriasis 13

Drugs for Psoriasis 13 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 440)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
carbamide peroxide Approved Phase 4 124-43-6
6
Desoximetasone Approved Phase 4 382-67-2 5311067
7
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
8
Clocortolone Approved Phase 4 4828-27-7, 34097-16-0 5282493 5311052
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
11 Strawberry Approved Phase 4
12 Orange Approved Phase 4
13 Artichoke Approved Phase 4
14
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
15
Abatacept Approved Phase 4 332348-12-6 10237
16
Zinc Approved, Investigational Phase 4 7440-66-6 32051
17
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18 Brodalumab Approved, Investigational Phase 4 1174395-19-7
19
Metformin Approved Phase 4 657-24-9 14219 4091
20
Ustekinumab Approved, Investigational Phase 4 815610-63-0
21 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
22 Vedolizumab Approved Phase 4 943609-66-3
23
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
24
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
25
Tofacitinib Approved, Investigational Phase 4 477600-75-2
26
Adalimumab Approved Phase 4 331731-18-1 16219006
27
Certolizumab pegol Approved Phase 4 428863-50-7
28
Mercaptopurine Approved Phase 4 50-44-2 667490
29
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
30
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
31
Capsaicin Approved Phase 4 404-86-4 1548943
32
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
35 Retinol palmitate Phase 4
36 retinol Phase 4
37 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
38 Omega 3 Fatty Acid Phase 4
39 Chelating Agents Phase 4
40 Tin Fluorides Phase 4
41 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
42 Halobetasol Phase 4
43
Chondroitin Phase 4 9007-27-6 53477707
44 Clocortolone pivalate Phase 4
45 Olive Phase 4
46 Citrate Phase 4
47 diuretics Phase 4
48 Anticoagulants Phase 4
49 Lidocaine, Prilocaine Drug Combination Phase 4
50 Pyrithione zinc Phase 4

Interventional clinical trials:

(show top 50) (show all 1686)
# Name Status NCT ID Phase Drugs
1 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
2 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
3 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
4 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
5 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
6 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
7 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
8 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
9 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
10 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
11 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
12 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
13 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
14 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
15 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
16 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
17 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
18 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
19 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
20 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
21 Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris Completed NCT00216892 Phase 4 Calcipotriol, (calcipotriol + betamethasone)
22 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
23 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
24 Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris Completed NCT02004574 Phase 4 Calcipotriol/betamethasone dipropionate gel
25 A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis Completed NCT02125279 Phase 4 Calcitriol
26 A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color Completed NCT03506477 Phase 4 Enstilar® foam;Vehicle foam
27 A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed NCT03331835 Phase 4 Fumaric acid esters
28 A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris Completed NCT00640393 Phase 4 Etanercept
29 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed NCT01707043 Phase 4 Taclonex
30 A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy Completed NCT01761019 Phase 4 Taclonex Topical Suspension
31 Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis Completed NCT03348462 Phase 4 ethosomal preparation of anthralin;liposomal preparation of anthralin
32 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00791765 Phase 4
33 Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis Completed NCT00332332 Phase 4
34 A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
35 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
36 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
37 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
38 A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept
39 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial Completed NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
40 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
41 Elocon vs Fluticasone in Localized Psoriasis Completed NCT00763529 Phase 4 Mometasone;Fluticasone
42 Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept Completed NCT00581165 Phase 4 Etanercept
43 A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis Completed NCT03573323 Phase 4 Ixekizumab;Guselkumab;Placebo
44 Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis Completed NCT00669123 Phase 4 Chondroitin sulphate;Placebo
45 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
46 An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days Completed NCT01714544 Phase 4 Cloderm Cream
47 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00287118 Phase 4 Efalizumab
48 Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed NCT00658606 Phase 4 alefacept
49 An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis Completed NCT02985736 Phase 4 Topicort Topical Spray
50 A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis Completed NCT00842153 Phase 4 Clobetasol propionate foam;Vehicle foam

Search NIH Clinical Center for Psoriasis 13

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Genetic Tests for Psoriasis 13

Genetic tests related to Psoriasis 13:

# Genetic test Affiliating Genes
1 Psoriasis Susceptibility 13 29 TRAF3IP2

Anatomical Context for Psoriasis 13

MalaCards organs/tissues related to Psoriasis 13:

40
Skin, Testes, T Cells, Liver, Bone, Endothelial, Monocytes

Publications for Psoriasis 13

Articles related to Psoriasis 13:

(show all 17)
# Title Authors PMID Year
1
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. 6 56
20953186 2010
2
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. 6 56
20953188 2010
3
An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. 6
24120361 2013
4
CIKS/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis. 6
22581863 2012
5
[Pruritus in Germany-a Google search engine analysis]. 61
29876613 2019
6
Juvenile psoriasis: an epidemiological study of 69 cases. 61
27374182 2018
7
Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. 61
30214261 2018
8
Remission of psoriasis 13 years after autologous stem cell transplant. 61
26125223 2015
9
Increased subclinical atherosclerosis in patients with chronic plaque psoriasis. 61
25463081 2014
10
Severely photosensitive psoriasis: a phenotypically defined patient subset. 61
19536141 2009
11
[The anti-tubercular drugs in the treatment of psoriasis]. 61
19801725 2009
12
An exploratory population-based case-control study of primary biliary cirrhosis. 61
10796879 2000
13
Narrowband UVB phototherapy for psoriasis: results with fixed increments by skin type (as opposed to percentage increments). 61
10321520 1999
14
The chemotactic activity of T-lymphocytes in response to interleukin 8 is significantly decreased in patients with psoriasis and atopic dermatitis. 61
9028795 1996
15
[Psoriasis: development and fatal complications]. 61
2048897 1991
16
[Comparative study between 120 mg. of anapsos and a placebo in 37 psoriasis patients]. 61
6759814 1982
17
Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study. 61
781848 1976

Variations for Psoriasis 13

ClinVar genetic disease variations for Psoriasis 13:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TRAF3IP2 NM_147686.4(TRAF3IP2):c.28G>A (p.Asp10Asn)SNV Benign 30630 rs33980500 6:111913262-111913262 6:111592059-111592059

UniProtKB/Swiss-Prot genetic disease variations for Psoriasis 13:

73
# Symbol AA change Variation ID SNP ID
1 TRAF3IP2 p.Asp19Asn VAR_047349 rs33980500

Expression for Psoriasis 13

Search GEO for disease gene expression data for Psoriasis 13.

Pathways for Psoriasis 13

GO Terms for Psoriasis 13

Sources for Psoriasis 13

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....